opc 21268 has been researched along with phenylephrine in 2 studies
| Studies (opc 21268) | Trials (opc 21268) | Recent Studies (post-2010) (opc 21268) | Studies (phenylephrine) | Trials (phenylephrine) | Recent Studies (post-2010) (phenylephrine) |
|---|---|---|---|---|---|
| 133 | 3 | 6 | 13,797 | 857 | 2,083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harada, S; Hirooka, Y; Imaizumi, T; Masaki, H; Momohara, M; Takeshita, A | 2 |
2 other study(ies) available for opc 21268 and phenylephrine
| Article | Year |
|---|---|
Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans.
Topics: Administration, Oral; Adult; Angiotensin Receptor Antagonists; Arginine Vasopressin; Dose-Response Relationship, Drug; Forearm; Humans; Injections, Intra-Arterial; Male; Phenylephrine; Piperidines; Quinolones; Receptors, Vasopressin; Regional Blood Flow; Vascular Resistance | 1992 |
Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Pressure; Heart Rate; Injections, Intravenous; Kidney; Male; Neural Inhibition; Phenylephrine; Piperidines; Quinolones; Rabbits; Sympathetic Nervous System; Vasopressins | 1993 |